Interaction between PPARA genotype and β-blocker treatment influences clinical outcomes following acute coronary syndromes

Pharmacogenomics

Volumn 9, Issue 10, 2008, Pages 1403-1417

  Cresci, Sharon ^a   Jones, Philip G ^b   Sucharov, Carmen C ^c   Marsh, Sharon ^a   Lanfear, David E ^d   Garsa, Adam ^a   Courtois, Michael ^a   Weinheimer, Carla J ^a   Wu, Jun ^a   Province, Michael A ^a   Kelly, Daniel P ^a   McLeod, Howard L ^e   Spertus, John A ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^e University of North Carolina   (United States)

Author keywords

adrenergic receptors; blockers; Acute coronary syndrome; Myocardial ischemia; Peroxisome proliferator activated receptor ; Pharmacogenetics; PPAR

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DOBUTAMINE; LABETALOL; MESSENGER RNA; METOPROLOL; NADOLOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROPRANOLOL; SOTALOL;

ACUTE CORONARY SYNDROME; ADRENERGIC SYSTEM; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONOTROPISM; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; FEMALE; GENE EXPRESSION; GENETIC HETEROGENEITY; GENETIC RISK; GENOTYPE; HAPLOTYPE; HEART MUSCLE CONTRACTILITY; HETEROZYGOTE; HOMOZYGOSITY; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENIC MOUSE; WILD TYPE;

ACUTE CORONARY SYNDROME; ADRENERGIC BETA-ANTAGONISTS; AGED; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; GENE FREQUENCY; GENES; GENOTYPE; HAPLOTYPES; HETEROZYGOTE; HOMOZYGOTE; HOSPITALIZATION; HUMANS; LINKAGE (GENETICS); MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR ALPHA; PROSPECTIVE STUDIES; REGISTRIES; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME;

MUS MUSCULUS;

EID: 55449125847     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.10.1403     Document Type: Article

References (36)

1. Krumholz HM, Anderson JL, Brooks NH et al.: ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction. A report of the American College of Cardiology/ American Heart Association Task Force on Performance Measures (writing committee to develop performance measures on st-elevation and non-st-elevation myocardial infarction). Circulation 113(5), 732-761 (2006).
2. Spertus JA, Eagle KA, Krumholz HM, Mitchell KR, Normand SL: American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care. Circulation 111, 1703-1712 (2005).
3. Cannon CP, Battler A, Brindis RG et al.: American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J. Am. Coll. Cardiol. 38, 2114-2130 (2001).
4. Ellison KE, Gandhi G: Optimising the use of β-adrenoceptor antagonists in coronary artery disease. Drugs 65, 787-797 (2005).
5. Thattassery E, Gheorghiade M: β-blocker therapy after acute myocardial infarction in patients with heart failure and systolic dysfunction. Heart Fail. Rev. 9, 107-113 (2004).
6. Chen ZM, Pan HC, Chen YP et al.: Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366, 1622-1632 (2005).
7. McDonald CG, Majumdar SR, Mahon JL, Johnson JA: The effectiveness of β-blockers after myocardial infarction in patients with Type 2 diabetes. Diabetes Care 28, 2113-2117 (2005).
8. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA: β2-adrenergic receptor genotype and survival among patients receiving β-blocker therapy after an acute coronary syndrome. JAMA 294, 1526-1533 (2005).
9. Lemberger T, Saladin R, Vazquez M et al.: Expression of the peroxisome proliferator-activated receptor α gene is stimulated by stress and follows a diurnal rhythm. J Biol. Chem. 271, 1764-1769 (1996).
10. Finck BN, Han X, Courtois M et al.: A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl Acad. Sci. USA 100, 1226-1231 (2003).
11. Panagia M, Gibbons GF, Radda GK, Clarke K: PPAR-α activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am. J. Physiol. Heart Circ. Physiol. 288, H2677-H2683 (2005).
12. Huss JM, Kelly DP: Mitochondrial energy metabolism in heart failure: a question of balance. J. Clin. Invest. 115, 547-555 (2005).
13. 2-dependent modulation of mitochondrial fatty acid oxidation. J. Biol. Chem. 276, 27605-27612 (2001).
14. Leone TC, Weinheimer CJ, Kelly DP: A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders. Proc. Natl. Acad. Sci. USA 96, 7473-7478 (1999).
15. Dewald O, Sharma S, Adrogue J et al.: Downregulation of peroxisome proliferator-activated receptor-α gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity. Circulation 112, 407-415 (2005).
16. Wallhaus TR, Taylor M, DeGrado TR et al.: Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 103, 2441-2446 (2001).
17. Panchal AR, Stanley WC, Kerner J, Sabbah HN: β-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. J. Card. Fail. 4, 121-126 (1998).
18. Flavell DM, Jamshidi Y, Hawe E et al.: Peroxisome proliferator-activated receptor α gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 105, 1440-1445 (2002).
19. Jamshidi Y, Montgomery HE, Hense HW et al.: Peroxisome proliferator - activated receptor α gene regulates left ventricular growth in response to exercise and hypertension. Circulation 105, 950-955 (2002).
20. Zak I, Balcerzyk A, Sarecka B, Niemiec P, Ciemniewski Z, Dylag S: Contemporaneous carrier-state of two or three proatherosclerotic variants of APOE, ICAM1, PPARA and PAI-1 genes differentiate CAD patients from healthy individuals. Clin. Chim. Acta 362, 110-118 (2005).
21. Cresci S: The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics. Expert Opin. Pharmacother. 6, 2577-2591 (2005).
22. Flavell DM, Ireland H, Stephens JW et al.: Peroxisome proliferator-activated receptor α gene variation influences age of onset and progression of Type 2 diabetes. Diabetes 54, 582-586 (2005).
23. Spertus J, Safley D, Garg M, Jones P, Peterson ED: The influence of race on health status outcomes one year after an acute coronary syndrome. J. Am. Coll. Cardiol. 46, 1838-1844 (2005).
24. Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J. Am. Coll. Cardiol. 36, 959-966 (2000).
25. Braunwald E: Unstable angina. A classification. Circulation 80, 410-414 (1989).
26. Antman EM, Cohen M, Bermnk PJ et al.: The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 284, 835-842 (2000).
27. Marsh S, King CR, Garsa AA, McLeod HL: Pyrosequencing of clinically relevant polymorphisms. Methods Mol. Biol. 311, 97-114 (2005).
28. Finck BN, Lehman JJ, Leone TC et al.: The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109, 121-130 (2002).
29. Leone TC, Lehman JJ, Finck BN et al.: PGC-1α deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 3, E101 (2005).
30. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA: Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet. 70, 425-434 (2002).
31. Harrell FE Jr: Regression Modeling Strategies. Springer, NY, USA (2001).
32. R Development Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria (2005).
33. Chen S, Tsybouleva N, Ballantyne CM, Gotto AM Jr, Marian AJ: Effects of PPARα, γ and δ haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics 14, 61-71 (2004).
34. Flavell DM, Pineda Torra I, Jamshidi Y et al.: Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 43,, 673-680 (2000).
35. Tai ES, Demissie S, Cupples LA et al.: Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 22, 805-810 (2002).
36. Gislason GH, Rasmussen JN, Abildstrom SZ et al.: Long-term compliance with β-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur. Heart J. 27, 1153-1158 (2006).